1. Home
  2. GKOS vs PECO Comparison

GKOS vs PECO Comparison

Compare GKOS & PECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$100.96

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo Phillips Edison & Company Inc.

PECO

Phillips Edison & Company Inc.

HOLD

Current Price

$36.71

Market Cap

4.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
PECO
Founded
1998
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
4.8B
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
GKOS
PECO
Price
$100.96
$36.71
Analyst Decision
Strong Buy
Buy
Analyst Count
14
8
Target Price
$133.07
$38.63
AVG Volume (30 Days)
577.7K
710.4K
Earning Date
04-29-2026
04-23-2026
Dividend Yield
N/A
3.47%
EPS Growth
N/A
74.51
EPS
N/A
0.89
Revenue
$507,442,000.00
$726,594,000.00
Revenue This Year
$23.34
$6.22
Revenue Next Year
$27.46
$3.85
P/E Ratio
N/A
$42.13
Revenue Growth
32.33
9.86
52 Week Low
$73.16
$32.40
52 Week High
$130.23
$40.06

Technical Indicators

Market Signals
Indicator
GKOS
PECO
Relative Strength Index (RSI) 37.84 31.12
Support Level $94.92 $34.44
Resistance Level $104.66 $40.06
Average True Range (ATR) 4.02 0.66
MACD -0.71 -0.31
Stochastic Oscillator 22.45 4.89

Price Performance

Historical Comparison
GKOS
PECO

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About PECO Phillips Edison & Company Inc.

Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.

Share on Social Networks: